Live Attenuated Vaccines Market Report 2026

The live attenuated vaccines market size has grown strongly in recent years. It will grow from $25.95 billion in 2025 to $28.52 billion in 2026 at a compound annual growth rate (CAGR) of 9.9%. The growth in the historic period can be attributed to global infectious disease burden, government immunization initiatives, childhood vaccination policies, hospital-based vaccine delivery, WHO vaccination programs.

The live attenuated vaccines market size is expected to see strong growth in the next few years. It will grow to $41.11 billion in 2030 at a compound annual growth rate (CAGR) of 9.6%. The growth in the forecast period can be attributed to booster vaccination demand, emerging infectious disease risks, cold chain infrastructure expansion, global health funding, next-generation vaccine platforms. Major trends in the forecast period include expansion of national immunization programs, growing demand for pediatric vaccination, advances in vaccine stability and storage, increased focus on pandemic preparedness, multivalent vaccine development.

The increasing prevalence of infectious diseases is expected to drive growth in the live attenuated vaccines market in the coming years. Infectious diseases are illnesses caused by harmful microorganisms, including bacteria, viruses, fungi, or parasites, which can spread directly or indirectly between people, animals, or the environment. Rising global travel accelerates the spread of these diseases by enabling pathogens to cross borders faster than containment efforts can respond. Live attenuated vaccines prevent infectious diseases by stimulating a strong immune response using weakened pathogens, ensuring long-term immunity and reducing transmission. For example, in March 2025, according to the World Health Organization, a Switzerland-based intergovernmental organization, approximately 10.8 million people worldwide contracted tuberculosis in 2023, including 6 million men, 3.6 million women, and 1.3 million children. Therefore, the rising prevalence of infectious diseases is driving growth in the live attenuated vaccines market.

Major companies in the live attenuated vaccines market are focusing on advanced products, such as single-dose vaccines, to enhance immunization efficiency and improve patient compliance. Single-dose vaccines provide lasting immunity with just one shot, eliminating the need for multiple doses and simplifying vaccination for both patients and healthcare providers. For instance, in November 2023, Valneva SE, a France-based biotech company, launched IXCHIQ, which received approval from the U.S. Food and Drug Administration (FDA). IXCHIQ is the world’s first live-attenuated chikungunya vaccine for adults aged 18 and older, addressing an unmet need for protection against this mosquito-borne viral disease that can cause severe fever, joint and muscle pain, and other symptoms.

In May 2023, Bavarian Nordic A/S, a Denmark-based biotechnology company, acquired a travel health business from Emergent BioSolutions Inc. for approximately $380 million. This acquisition expanded Bavarian Nordic’s vaccine portfolio to include VIVOTIF for typhoid fever, VAXCHORA for cholera, and the chikungunya vaccine candidate CHIKV VLP, along with associated manufacturing and development facilities in Switzerland and California. Emergent BioSolutions Inc., based in the U.S., specializes in manufacturing live attenuated vaccines.

Major companies operating in the live attenuated vaccines market are Merck & Co. Inc., Sanofi SA, AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, CSL Limited, GC Biopharma, Serum Institute of India Pvt. Ltd., Bavarian Nordic, Valneva SE, Southern Research, BioFarma, Bharat Biotech International Limited, Meissa Vaccines Inc., BioDiem Ltd., Bio-Med Limited, Naobios, Lakshmi Pharmaceuticals.

North America was the largest region in the live attenuated vaccines market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the live attenuated vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the live attenuated vaccines market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the live attenuated vaccines market by increasing expenses related to viral seed strains, bioreactor consumables, cold-chain packaging, and international vaccine transport. Pediatric immunization programs and mass vaccination campaigns are most affected, particularly in Asia-Pacific and North America where cross-border vaccine supply chains are common. Hospitals, clinics, and public health distributors experience higher vaccine procurement costs. However, tariffs are accelerating domestic vaccine production and regional fill-and-finish capabilities, improving national vaccine security.

The live attenuated vaccines market research report is one of a series of new reports that provides live attenuated vaccines market statistics, including live attenuated vaccines industry global market size, regional shares, competitors with a live attenuated vaccines market share, detailed live attenuated vaccines market segments, market trends and opportunities, and any further data you may need to thrive in the live attenuated vaccines industry. This live attenuated vaccines market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Live attenuated vaccines are biological formulations that contain a weakened form of a virus or bacterium, engineered in the lab to prevent it from causing illness in healthy individuals. By closely mimicking a natural infection, these vaccines elicit a strong and long-lasting immune response, often requiring only one or two doses for effective protection against infectious diseases.

The main types of live attenuated vaccines include monovalent and multivalent vaccines. Monovalent vaccines target a single specific antigen, strain, or type. They are administered via intramuscular, subcutaneous, oral, or intranasal routes for various indications, including influenza, measles, mumps, rubella (MMR), polio, chickenpox, shingles, rotavirus, and others. These vaccines are distributed through hospital pharmacies, retail pharmacies, and online pharmacies, and are used by hospitals, clinics, diagnostic centers, research institutes, and other healthcare providers.

The live attenuated vaccine market consists of sales of viral live attenuated vaccines, bacterial live attenuated vaccines, and intranasal live attenuated vaccines. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.